Table 4.

Secondary outcomes: progression/regression of mRSS and decline/increase of FVC

	mRSS		FVC
	Progression	Regression	Decline	Increase
Estimated treatment effect of TCZ with OR (95% CI)	0.7 (0.1 to 4.8)	1.1 (0.4 to 2.7)	0.8 (0.3 to 2.2)	1.5 (0.6 to 3.8)
P values	0.74	0.86	0.63	0.41

These results represent our main analysis with a nearest neighbour matching algorithm and selection of most recent observation in control patients with multiple possible baseline observations.

CI, confidence interval; FVC, forced vital capacity; mRSS, modified Rodnan skin score; OR, odds ratio; TCZ, tocilizumab.